CAREFOR, The Clinical Academic Cancer Research Forum
Indication Lymphome agressif à cellules B récidivant ou ... - CHUV
Home | SAKK
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. | Semantic Scholar
SAKK | BIG against breast cancer
Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer
SCTO Platforms - scto
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small‐cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial | Semantic Scholar
Methods in Clinical Cancer Research (MCCR) 2021 | ESMO
BIG Members | Breast International Group
SAKK/Pfizer Award
Organization
Francesco Bertoni has been elected as President of the Lymphoma Project Group of Swiss Group for Clinical Cancer Research
Home | SAKK
Talidox | InnoMedica
Long‐term outcome of dasatinib first‐line treatment in gastrointestinal stromal tumor: A multicenter, 2‐stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07) - Montemurro - 2018 - Cancer - Wiley Online Library
Swiss Medical Weekly - Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer
SAKK Swiss Group for Clinical Cancer Research | LinkedIn
International Journal of Colorectal Disease | Volume 32, issue 1
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. | Semantic Scholar
PDF) Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer
Swiss Group for Clinical Cancer Research (SAKK) – Breast Cancer Project Group | Breast Cancer Online | Cambridge Core
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK - ScienceDirect
